权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Training Program in Basic Cancer Research

基础癌症研究培训计划

基本信息

批准号：
10654720
负责人：
Alessandro Gardini
金额：
$ 38.95万
依托单位：
WISTAR INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
1976
资助国家：
美国
起止时间：
1976-07-01 至 2027-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10654720
关键词：
Basic Cancer Research Training Programs

项目摘要

Project Summary The overarching goal of this longstanding “Training Program in Basic Cancer Research” is to provide the fundamental skills necessary for our trainees to succeed in outstanding careers in biomedical cancer research. Toward that goal we provide them with superior training in the conduct of cutting edge research, combined with a deep appreciation of the clinical challenges that doctors and patients face. To achieve this goal, we have created a unique Training program, now entering its 45th year, entitled the Training Program in Basic Cancer Research (TP-BCR). Support is requested for five postdoctoral fellows, and three predoctoral fellows from the University of Pennsylvania Perelman School of Medicine, program in Biomedical Graduate Studies. Located at the heart of the University of Pennsylvania campus, Wistar offers a superb research environment, recently rated “Exceptional” at the most recent CCSG renewal in 2018. We have crafted a training program that combines unique sub-programs entitled “Bench to Bedside Training” and a “Science Entrepreneurs” program, thus offering our trainees exposure to clinicians and clinical problems in cancer research, unique insight into the business of science and intellectual property, and a robust curriculum that includes workshops in teaching, writing, and grant preparation. Our 26 faculty mentors tackle diverse questions in cancer, most have long-standing successful training records, and all are well-funded, with an average of $890,000/year/mentor (DC). Our current trainee pool consists of 79 trainees, which includes 24 predoctoral trainees (13 TGE) and 55 postdoctoral trainees (20 TGE). There is an average of four TGE applicants for each proffered slot, thus allowing us to place the most highly qualified trainees in this program. All slots have been continuously filled for the entire funding period, and our trainees continue to be highly productive, with 4.7 manuscripts and 2 first author manuscripts per trainee averaged in the past three cycles, and 98% of our trainees continuing in research-related or research-intensive careers. Taken together, this long-standing program, which is the only T32 centered at The Wistar Institute, will provide the fundamental skills necessary for our trainees to flourish in successful independent careers in cancer research.

项目摘要这一长期的“基础癌症研究培训计划”的首要目标是提供学员在生物医学癌症领域取得成功所需的基本技能研究。为了实现这一目标，我们为他们提供了先进的尖端技术培训研究，结合对医生和患者面临的临床挑战的深刻认识。至为了实现这一目标，我们创建了一个独特的培训计划，现已进入第45个年头，名为癌症基础研究培训计划(TP-BCR)。请求支持五名博士后宾夕法尼亚大学佩雷尔曼医学院的三名博士后研究员，生物医学研究生课程。位于宾夕法尼亚大学校园的中心， Wistar提供了一流的研究环境，最近在最新的CCSG中被评为“卓越” 2018年续签。我们已经制定了一个培训计划，其中结合了独特的子计划，名为“板凳到床上培训“和”科学企业家“计划，从而使我们的实习生接触到临床医生和癌症研究中的临床问题，对科学和商业的独特见解知识产权，以及强大的课程，其中包括教学、写作和授权方面的研讨会准备工作。我们的26名教师导师解决了癌症方面的各种问题，大多数人都有很长的历史成功的培训记录，所有的资金都很充足，平均为89万美元/年/导师(DC)。我们的目前的实习生人才库由79名实习生组成，其中包括24名博士前实习生(13名TGE)和55名博士后实习生(20名)。每个录取名额平均有四名TGE申请人，因此使我们能够将最合格的学员安排在这个项目中。所有插槽都已连续在整个资助期内都被填满了，我们的学员继续保持着很高的生产力，有4.7份手稿在过去的三个周期中，每个学员平均有2篇第一作者手稿，98%的学员继续从事与研究相关或研究密集型的职业。综上所述，这个由来已久该计划是唯一以Wistar研究所为中心的T32计划，将提供基本技能对于我们的受训人员在癌症研究领域成功的独立职业生涯中取得成功来说，这是必要的。

项目成果

期刊论文数量（75）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates.

使用 INO-4800 和 INO-4802 的初免加强疫苗接种方案可增强和扩大非人灵长类动物针对 SARS-CoV-2 的免疫反应。

DOI：
10.1016/j.vaccine.2022.03.060
发表时间：
2022-05-09
期刊：
Vaccine
影响因子：
5.5
作者：
Walters JN;Schouest B;Patel A;Reuschel EL;Schultheis K;Parzych E;Maricic I;Gary EN;Purwar M;Andrade VM;Doan A;Elwood D;Eblimit Z;Nguyen B;Frase D;Zaidi FI;Kulkarni A;Generotti A;Joseph Kim J;Humeau LM;Ramos SJ;Smith TRF;Weiner DB;Broderick KE
通讯作者：
Broderick KE

Point mutations of the adenovirus major late promoter with different transcriptional efficiencies in vitro.

腺病毒主要晚期启动子的点突变在体外具有不同的转录效率。